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ABSTRACT
Castration resistance is a major obstacle to hormonal therapy for prostate cancer 
patients. Although androgen independence of prostate cancer growth is a known 
contributing factor to endocrine resistance, the mechanism of androgen receptor 
deregulation in endocrine resistance is still poorly understood. Herein, the CAMK2N1 
was shown to contribute to the human prostate cancer cell growth and survival 
through AR-dependent signaling. Reduced expression of CAMK2N1 was correlated to 
recurrence-free survival of prostate cancer patients with high levels of AR expression 
in their tumor. CAMK2N1 and AR signaling form an auto-regulatory negative feedback 
loop: CAMK2N1 expression was down-regulated by AR activation; while CAMK2N1 
inhibited AR expression and transactivation through CAMKII and AKT pathways. 
Knockdown of CAMK2N1 in prostate cancer cells alleviated Casodex inhibition of 
cell growth, while re-expression of CAMK2N1 in castration-resistant cells sensitized 
the cells to Casodex treatment. Taken together, our findings suggest that CAMK2N1 
plays a tumor suppressive role and serves as a crucial determinant of the resistance 
of prostate cancer to endocrine therapies.
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INTRODUCTION
Prostate cancer is one of the most common 
malignancies in men. As the average life expectancy 
has been prolonged, the incidence and mortality rates 
of prostate cancer have increased significantly in recent 
years [1]. The progression of prostate cancer normally 
goes from castration-sensitive to castration-resistant, 
inevitably developing highly metastatic properties [2]. 
Prostate tumors initially respond to hormonal intervention 
therapies, however, as androgen-independence emerges, 
tumors develop resistance [3]. The main treatments for 
advanced prostate cancer consist of hormone therapy, 
chemotherapy and/or radiation. Unfortunately, although 
the diagnosis of cancer has advanced, limited therapy 
options stall are stalling the survival rates in patients [4, 
5].
 The CAMK2N1 gene, cloned and characterized as 
an inhibitor of CaMKII (calcium/calmodulin-dependent 
protein kinase II), has been shown to affect tumorigenesis 
and tumor growth [6, 7]. In a prior study, we demonstrated 
that CAMK2N1 expression was reduced in prostate 
cancer, and re-introduction of CAMK2N1 significantly 
impaired human prostate cancer cell proliferation and 
tumor growth in vivo [8]. Genome-wide gene profiling 
revealed that CAMK2N1 regulated the expression of key 
genes associated with cell-cycle progression and apoptosis 
[8]. Furthermore, CAMK2N1 suppressed androgen 
receptor (AR) mRNA levels and AR regulators such as 
IGF-1, ErbB2, AKT, and HSP27 [8]. This data suggests 
that CAMK2N1 plays an important role in the progression 
of prostate cancer. However, the molecular mechanisms 
and functional link between CAMK2N1 and AR signaling 
is still unknown.
In this study, we observed CAMK2N1 and AR 
signaling form an auto-regulatory negative feedback loop 
in human prostate cancer cells. CAMK2N1 expression 
was inversely correlated with AR levels in prostate 
cancer, and patients with higher CAMK2N1 expression 
in their tumor have improved recurrence-free survival. 
Importantly, ectopic expression of CAMK2N1 in 
castration-resistant prostate cancer cells sensitized cells to 
response to anti-androgen treatment. Taken together, our 
findings revealed a tumor suppressive role for CAMK2N1 
and established CAMK2N1 as molecular determinant in 
hormone sensitivity of prostate cancer.
RESULTS 
A significant negative correlation between 
CAM2KN1 and AR in clinical prostate cancer 
specimens
The androgen receptor (AR) is a ligand-activated 
transcription factor, which plays critical roles in normal 
prostate development and prostate tumorigenesis [3]. 
The growth of advanced prostate cancer (both castration-
sensitive prostate cancer (CSPC) and castration-resistant 
prostate cancer (CRPC)) depends on androgen receptor 
signaling. In our prior study, CAMK2N1 suppressed 
the expression of AR (mRNA levels) and AR regulators 
including IGF-1, ErbB2, JAK and HSP27 [8]. However, 
the clinical significance of these observations has not 
been investigated. We first performed in silico analysis 
for AR and CAMK2N1 expression on a clinical gene-
expression array dataset composed of 154 patient samples 
with follow-up information (Supplemental Figure 1A) [9]. 
The Kaplan-Meier analysis was conducted to evaluate the 
difference in recurrence-free survival associated with high 
versus low expression of AR and CAMK2N1 gene. Genes 
that correspond to the AR and CAMK2N1 signature were 
used to assign the samples as high (upper 25th percentile) 
or low (lower 75th percentile) [10]. In Kaplan-Meier 
analysis for AR, patients with tumors expressing high AR 
(n = 39) had significantly lower recurrence-free survival 
(p = 0.0006) (Figure. 1A). In recurrent patients with high 
AR expression (p = 0.023), there was a significant trend 
toward improved survival of those patients with high 
expression of CAMK2N1 (n = 19) compared to those with 
low CAMK2N1 expression (n = 20) in tumors (Figure. 
1B). As revealed by IHC to determine the expression of 
AR and CAMK2N1 in the prostate cancer specimens 
(n=70) [8]. AR and CAMK2N1 were inversely correlated 
in human prostate cancer (r = -0.384, p = 0.0027) (Figure. 
1C-D). Taken together, these results suggested a functional 
interaction between CAMK2N1 and AR during prostate 
cancer progression.
CAMK2N1 expression was down-regulated by 
androgen/AR signaling
The inverse correlation between AR and CAMK2N1 
raised a possibility that CAMK2N1 may functionally 
interact with androgen/AR signaling. To explore this 
possibility, we first determined whether androgen 
signaling affects CAMK2N1 expression. Castration-
sensitive prostate cancer cells LNCaP and castration-
resistant prostate cancer cells C4-2 were treated with 
1-10 nM of R1881 for 6-10 hrs and the total RNA was 
isolated. As shown in Fig. 2A-B, Supplemental Figure 
2A, qRT-PCR analysis revealed that CAMK2N1 mRNA 
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levels were decreased upon androgen treatment in LNCaP 
cells. In addition, we searched the microarray data in the 
public domains for effects of androgens on CAMK2N1 
mRNA expression in AR-positive prostate cancer cell lines 
[11, 12], and similar observation was also made in this 
database (Supplemental Figure 2B). Next, our western 
blot and qRT-PCR analysis showed that CAMK2N1 
protein and mRNA levels were decreased in cells treated 
with androgen, and androgen inhibition of CAMK2N1 
was alleviated by shRNA-mediated AR knockdown (Fig. 
2C-E). Collectively, these observations indicate that 
CAMK2N1 is an androgen-responsive gene, which is 
down regulated by AR activation. 
We further performed luciferase reporter assays 
to evaluate the effect of androgen/AR signaling on 
CAMK2N1 transactivation. The CAMK2N1 promoter 
reporters (-39~-1011, -1112~-2006) were assessed in 
AR-positive LNCaP cells and AR-negative PC3 cells. 
R1881 repressed activity of CAMK2N1 gene reporters 
(-39~-1011, but not -1112~-2006) in the presence of AR 
(Fig. 2F-H). Taken together, these findings indicated that 
CAMK2N1 expression and transactivation were down-
regulated by androgen/AR signaling. 
CAMK2N1 inhibited AR expression and 
transactivation
In order to determine whether CAMK2N1 regulates 
AR signaling, we conducted western blot and qRT-
Figure 1: A significant negative correlation between CAM2KN1 and AR in prostate cancer specimens. (A) In Kaplan-
Meier analysis, patients with tumors expressing high levels of AR (N = 39) had poor recurrence-free survival (p = 0.0006). (B) In Kaplan-
Meier analysis, there was a significant trend toward improved survival in cases showing high expression of CAMK2N1 (N = 19) as opposed 
to cases showing low expression of CAMK2N1 (N = 20) in recurrent patients with high AR expression (p = 0.023). (C) IHC was also 
conducted to determine CAMK2N1 and AR expression in the prostate cancer specimens (N = 70). AR and CAMK2N1 were inversely 
correlated in human prostate cancers (r = -0.384, p = 0.0027).
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PCR analysis in LNCaP cells with stable knockdown 
of CAMK2N1. As shown in Fig. 3A, cells treated with 
AR agonist R1881 increased AR protein expression and 
decreased p21 expression. Depletion of CAMK2N1 
further enhanced AR expression levels in the presence and 
absence of the ligand. As shown in Fig. 3B-F, cells treated 
with AR agonist R1881 increased AR, AR target genes 
such as PSA and TMPRSS2 mRNA levels, and decreased 
p21 mRNA levels, and depletion of CAMK2N1 further 
enhanced AR, PSA and TMPRSS2 mRNA levels in the 
presence and absence of the ligand.
Furthermore, we conducted luciferase reporter 
assays to evaluate the effect of CAMK2N1 on AR 
transactivation. The androgen-responsive promoter 
reporters were assessed in AR-positive LNCaP cells where 
R1881 induced activity of androgen responsive gene 
Figure 2: CAMK2N1 expression was down-regulated by androgen/AR signaling. (A-B) LNCaP cells were treated with 1-100 
nM R1881 for 6-10 hrs. CAMK2N1 mRNA levels were determined by qRT-PCR. (C-E) CAMK2N1, AR protein and mRNA levels were 
determined by Western blot and qRT-PCR in LNCaP cells with stably knockdown of AR. LNCaP cells were treated with 10 nM R1881 for 
10 hrs. (F-H) CAMK2N1 promoter reporters (-39~-1011, -1112~-2006) were assessed in AR-positive LNCaP cells and AR-negative PC3 
cells. R1881 repressed activity of CAMK2N1 gene reporters (-39~-1011) in the presence of AR.
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reporters including PSA-Luc and MMTV-Luc (Fig. 3G-
J). Knockdown of CAMK2N1 increased R1881-induced 
PSA-Luc activity by 2-fold (Fig. 3G) and MMTV-Luc 
by 24-fold (Fig. 3H). Conversely, Overexpression of 
CAMK2N1 reduced R1881-induced reporter activity by 
50% (Fig. 3I-J). To examine the interaction between AR 
and CAMK2N1 in the context of local chromatin, we 
conducted chromatin immunoprecipitation (ChIP) assays. 
AR has been previously shown to bind to the enhancer 
elements of the PSA gene (-4153/-3570 bp) [13, 14]. Thus 
we performed ChIP analysis using anti-AR antibody to 
pull down PSA enhancer elements. As shown in Fig. 3K, 
shRNA-mediated knockdown of endogenous CAMK2N1 
increased AR binding to the PSA enhancer elements in 
an androgen-dependent manner. Taken together, these 
observations suggested that CAMK2N1 inhibits AR 
expression and AR-dependent transactivation.
Figure 3: CAMK2N1 inhibited AR expression and transactivation. (A) CAMK2N1, AR and p21 protein levels were determined 
by Western blot in LNCaP cells with stably knockdown of CAMK2N1. LNCaP cells were treated with 10 nM R1881 for 10 hrs. (B-
F) CAMK2N1, AR, PSA, TMPRSS2 and p21 mRNA levels were determined by qRT-PCR in LNCaP cells with stably knockdown of 
CAMK2N1. LNCaP cells were treated with 10 nM R1881 for 10 hrs. (G-J) Androgen-responsive luciferase reporter genes (PSA-Luc, 
MMTV-Luc) were assessed for AR activity. LNCaP cells with CAMK2N1 overexpression or knockdown were treated with R1881 for 24 
hrs. (K) CHIP analysis of AR for PSA promoter region in LNCaP cells with stable knockdown of CAMK2N1. LNCaP cells were treated 
with R1881 or vehicle for 10 hrs. CHIP assay was performed using an anti-AR antibody. 
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CAMK2N1-mediated suppression of AR 
transactivation is dependent on the CAMKII and 
AKT pathways 
We had previously shown that CAMK2N1 regulated 
cell proliferation and cell death signaling [8]. To validate 
CAMK2N1-regulated signaling pathways in CSPC cells, 
a subset of genes that were AR, AKT, pAKTser473, Bcl-2, 
p21 and Bax were determined by Western blot. Depletion 
of CAMK2N1 by shRNA in LNCaP cells resulted in 
increased AR, pAKTser473, and Bcl-2 expression and 
decreased p21 and Bax expression (Fig. 4A). Conversely, 
overexpression of CAMK2N1 in LNCaP cells led to an 
opposite effect on protein expression of these genes (Fig. 
4B).
Figure 4: CAMK2N1-mediated suppression of AR transactivation is dependent on the CAMKII and AKT pathways. 
(A) Expression levels of pAKTser473, AKT, AR, Bcl-2, BAX, and p21 were determined by Western blot in LNCaP cells with stable 
CAMK2N1 knockdown. (B) Expression levels of pAKTser473, AKT and AR were determined by Western blot in LNCaP cells with stable 
CAMK2N1 overexpression. (C-D) CAMK2N1 knockdown cells treated with 10 nM R1881 and/or 20µM KN-93 inhibitor. PSA-Luc was 
assessed for AR activity. CAMKIIβ and AR protein levels were determined by Western blot. (E-F) LNCaP cells transiently transfected 
with CAMK2N1 and/or CAMKIIβ while treated with 10 nM R1881. PSA-Luc was assessed for AR activity. CAMK2N1 and CAMKIIβ 
protein levels were determined by Western blot. (G-H) CAMK2N1 knockdown cells treated with 10 nM R1881 and/or 20 µM AKT VIII. 
PSA-Luc was assessed for AR activity. pAKTser473, AKT and AR β protein levels were determined by Western blot. (I-J) LNCaP cells 
transiently transfected with CAMK2N1 and/or m-AKT. PSA-Luc was assessed for AR activity. CAMK2N1 and CAMKIIβ protein levels 
were determined by Western blot. 
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CAMKII is a ubiquitous serine/threonine protein 
kinase that phosphorylates nearly 40 different proteins, 
including enzymes, ion channels, kinases and transcription 
factors [6, 7]. Previous study demonstrated that CAMKII 
regulates the PI3K/AKT pathway by phosphorylating 
AKT at Ser473 [15]. Inhibition of AKT phosphorylation 
and activity suppresses AR levels in prostate cancer [16]. 
The current study demonstrated that CAMK2N1, the 
inhibitor of CAMKII, inhibited AKT phosphorylation 
at Ser473 and repressed AR expression and activity. In 
order to further explore the functional interaction between 
CAMK2N1 and AR, we conducted luciferase reporter and 
Western blot to determine whether CAMK2N1-mediated 
suppression of AR activity is dependent on CAMKII and 
AKT signaling. As shown in Fig. 4C-D, Fig. 4G-H and 
Supplemental Figure 3G, knockdown of CAMK2N1 
increased R1881-induced PSA-Luc activity, whereas 
addition of CAMKII inhibitor (KN-93) or AKT inhibitor 
VIII abrogated the effects of CAMK2N1 knockdown on 
AR activity. Conversely, overexpression of CAMK2N1 
decreased R1881-induced PSA-Luc activity, while 
transient transfection of LNCaP cells with constitutively 
active CAMKIIβ or AKT (myrAKT) resulted in increased 
PSA-Luc activity (Fig. 4E-F and Fig. 4I-J). This data 
indicates that CAMK2N1-mediated suppression of 
AR transactivation is dependent on CAMKII and AKT 
signaling pathways.
We further analyzed the expression of CAMKIIα, 
CAMKIIβ, CAMKIIγ and CAMKIIδ genes in prostate 
cancer cell lines (LNCaP, C4-2, DU145, and PC3) by 
qRT-PCR (Supplemental Figure 3A-C). The prostate 
cancer cells exhibited increased expression of CAMKIIβ 
(Supplemental Figure 3A) compared to RWPE1, a normal 
prostate cell line. CAMKIIα expression was not detected 
in all prostate cell lines tested. Next, we used qRT-
PCR to determined whether suppression of CAMKII is 
mediated by CAMK2N1. We observed that knockdown of 
CAMK2N1 in LNCaP and C4-2 cells increased expression 
of CAMKII, while overexpression of CAMK2N1 in 
DU145 and PC3 cells decreased expression of CAMKII 
(Supplemental Figure 3D-F). These findings indicate 
that CAMK2N1 inhibits the expression of CAMKII 
(particularly the CAMKIIβ isoform) in prostate cancer 
cells.
CAMK2N1 contributes to castration-sensitive cell 
growth through AR-dependent signaling 
To determine the functional significance of 
CAMK2N1 in regulating the proliferation of AR-positive 
CSPC cells, we conducted MTT assays and found that 
knockdown of CAMK2N1 in LNCaP cells using shRNAs 
increased cell proliferation (Fig. 5A-B, Supplemental Fig. 
4A). 
AR agonist, R1881, stimulates castration-sensitive 
cell growth [17]. AR antagonist Casodex, a pharmaceutical 
drug commonly is used as an anti-androgen therapy to 
treat recurrent prostate cancer. The growth of castration-
sensitive cells is inhibited by Casodex. To further 
investigate whether CAMK2N1 inhibition of castration-
sensitive cell proliferation is dependent on AR, we 
knocked down CAMK2N1 in LNCaP cells followed by 
R1881 or Casodex treatment. As shown in Figure. 5A-
B, we observed that depletion of CAMK2N1 increased 
LNCaP cell growth in the presence of R1881, while 
alleviated inhibition of cell growth to Casodex. Taken 
together, this data suggests that AR-dependent signaling 
was involved in CAMK2N1 repression of castration-
sensitive cell proliferation.
FACS analysis was performed to further characterize 
the effects of CAMK2N1 on cell-cycle progression. We 
knocked down CAMK2N1 in LNCaP cells followed by 
R1881 treatment. Depletion of CAMK2N1 reduced the 
proportion of cells in G0/G1 but increased the proportion 
of cells in S-phase in the presence of R1881, while 
androgen-deprivation alleviated the effects of knockdown 
CAMK2N1, suggesting that AR-dependent signaling 
was involved in CAMK2N1 repression of cell cycle 
progression (Fig. 5C).
CAMK2N1 contributes to castration-resistant 
cell growth through AR-dependent signaling, and 
re-introduction of CAMK2N1 revert castration-
resistance of prostate cancer cells
To further validate CAMK2N1-regulated signaling 
pathways in CRPC cells, a subset of genes that were AR, 
AKT, pAKTser473, Bcl-2, p21 and Bax were determined 
by Western blot. Depletion of CAMK2N1 by shRNA in 
C4-2 cells resulted in increased AR, pAKTser473, and 
Bcl-2 expression and decreased p21 and Bax expression 
(Fig. 6A). Conversely, overexpression of CAMK2N1 in 
C4-2 cells led to an opposite effect on protein expression 
of these genes (Fig. 6B).
AR has been reported to promote cell proliferation 
and plays a critical role in the development of CRPC [3, 
18]. Knockdown of AR in castration-resistant C4-2 cells 
reduced cell growth [19]. To further investigate whether 
CAMK2N1 inhibition of CRPC cell proliferation is 
dependent on AR, we first knocked down CAMK2N1 in 
C4-2 cells. Depletion of CAMK2N1 increased C4-2 cell 
growth and promoted cell cycle progression (Fig. 6E, 
Supplemental Fig. 4B). Furthermore, we overexpressed 
CAMK2N1 with simultaneous depletion of AR in 
C4-2 cells. CAMK2N1 inhibited cell proliferation in 
the presence of endogenous AR (Fig. 6C), while AR 
knockdown alleviated the CAMK2N1 repression. This 
data suggests that AR-dependent signaling was involved 
in CAMK2N1 repression of cell proliferation. 
One of the hallmarks of prostate cancer treatment 
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failure is the development of castration resistance to anti-
androgen therapies. Ligand-independent AR activation 
contributed to the development of castration resistance 
[18, 20]. It has been shown that AKT phosphorylation 
and activity stimulated ligand-independent AR activation 
could contribute to castration resistant growth of 
prostate cancer cells [21, 22]. In our study, CAMK2N1-
mediated suppression of AR activation is dependent 
on the AKT pathway. To explore whether CAMK2N1 
inhibits ligand-independent AR activation and reverts 
castration resistance, we conducted MTT assays in C4-2 
cells treated with Casodex. As a competitive inhibitor of 
AR, Casodex prevents androgen binding to the AR by 
blocking its binding sites to the target gene promoter [23]. 
As a result, castration-resistant cells are refractory to this 
treatment [24, 25]. As shown in Figure. 6D, we observed 
that overexpression of CAMK2N1 induced inhibition 
of growth to Casodex in castration-resistant C4–2 cells, 
Figure 5: CAMK2N1 contributes to castration-sensitive cell growth through AR-dependent signaling. (A) LNCaP cells 
with stable knockdown of CAMK2N1 were treated with or without R1881. Cells were analyzed for cell proliferation by MTT assay. 
(B) LNCaP cells with stable knockdown of CAMK2N1 followed by treatment with or without Casodex (10 µM) were analyzed for cell 
proliferation by MTT assay. (C) LNCaP cells with stable knockdown of CAMK2N1 were treated with or without R1881. Cells were then 
analyzed for cell cycle by flow cytometry.
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indicating that expression of CAMK2N1 can restore 
Casodex sensitivity of prostate cancer cells. 
Since elevated cell death may also contribute 
to impaired tumor growth, we determined whether 
CAMK2N1 induces apoptosis through AR by Annexin 
V staining assays. We overexpressed CAMK2N1 with 
simultaneous depletion of AR in C4-2 cells. CAMK2N1 
induced cell apoptosis from 3%~8% in the presence of 
endogenous AR, while AR knockdown alleviated the 
CAMK2N1 induction from 8%~11% (Fig. 6F). This data 
suggests that AR-dependent signaling was involved in 
CAMK2N1 induction of cell apoptosis.
Figure 6: CAMK2N1 contributes to castration-resistant cell growth through AR-dependent signaling, and re-
introduction of CAMK2N1 revert castration-resistance of prostate cancer cells. (A) Expression levels of pAKTser473, AKT, 
AR, Bcl-2, BAX, and p21 were determined by Western blot in C4-2 cells with stable CAMK2N1 knockdown. (B) Expression levels of 
pAKTser473, AR Bcl-2, BAX, and p21 were determined by Western blot in C4-2 cells with stable CAMK2N1 overexpression. (C) C4-2 cells 
with stable overexpression of CAMK2N1 and AR knockdown. Cells were analyzed for cell proliferation by MTT assay. CAMK2N1 and 
AR protein levels were determined by Western blot. (D) C4-2 cells with stable overexpression of CAMK2N1 followed by treatment with or 
without Casodex (10 µM) were analyzed for cell proliferation by MTT. (E) C4-2 cells with stable knockdown of CAMK2N1 were analyzed 
for cell cycle by flow cytometry. (F) C4-2 cells with stable overexpression of CAMK2N1 and AR knockdown. Cells were analyzed for cell 
apoptosis by Annexin V staining.
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CAMK2N1 inhibits AR-positive prostate tumor 
growth in vivo 
To investigate the role of CAMK2N1 in inhibiting 
AR-positive prostate cancer growth in vivo, we 
established C4-2 cells stably transduced with lentiviral 
shRNAs targeting CAMK2N1. We implanted these cells 
subcutaneously into immune-deficient mice and monitored 
the tumor growth (Fig. 7A-C). Knockdown of CAMK2N1 
increased tumor size (Fig. 7A-B) and tumor weight (Fig. 
7C).
To determine the expression of CAMK2N1, AR, 
pAKTser473, PSA, Bax, Bcl-2, p21, and Ki67 in tumor 
tissues, we conducted qRT-PCR and IHC staining in 
tumors. As shown in Fig. 7D-E. Tumors with CAM2KN1 
knockdown have reduced expression of p21, Bax and 
increased AR, pAKTser473, PSA, Bcl-2 and Ki67 
expression, suggesting that reduction of CAM2KN1 
promotes growth in AR positive prostate cancer cells.
Figure 7: CAMK2N1 inhibits AR-positive prostate tumor growth in vivo. (A-C) C4-2 tumors with stable CAMK2N1 
knockdown were injected into nude mice. Tumor size was measured every 5 days. The data was shown as mean ± SEM for N > 6 separate 
tumors for each group. (A) Images of tumors dissected from the mice. (B) The tumor size (mm3) versus days of post injection. (C) Tumor 
was weighted after resection at the end of experiment. (D) mRNA levels of AR, PSA, P21, BAX and BCL2 were determined by qRT-PCR 
in tumors. (E) IHC staining detected the protein expression of CAMK2N1, AR, p21, Ki67, pAKTser473 and BCL2 in C4-2 tumor tissues 
derived from mice. Data for quantified IHC was shown as mean ± SEM for N = 4 tumors in each group.
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DISSCUSSION
AR plays a critical role in the development of 
CRPC. In CSPC, AR promotes cell proliferation through 
regulation of the G1/S transition [3, 18]. In CRPC, AR is 
thought to remain active through a variety of potential 
mechanisms including AR gene amplification, mutations, 
abnormal activation, and AR activator overexpression 
[4, 18]. Upregulation of AR activation in the absence of 
androgen is one of the mechanisms that lead to abnormal 
AR activation, which promotes CRPC development [26]. 
It has been previously shown that AKT serves as positive 
regulator of AR activity [22]. PI3K/AKT signaling 
pathways cooperate in prostate cancer progression and its 
transition to castration resistant disease [27]. Inhibition of 
PI3K/AKT pathways acts combinatory to inhibit tumor 
growth, cellular proliferation and migration of prostate 
cancer [28]. Overexpression of CAMK2N1 suppressed 
AKT and AR suggests that the loss of CAMK2N1 in 
advanced prostate cancer could be the primary cause of 
enhanced kinase signaling, which consequently leads to 
abnormal activation of AR.
Patients with high levels of AR expression in their 
tumors are usually associated with decreased recurrence-
free survival [29]. Thus, blocking AR expression and 
activation in clinical practice has become one of the most 
effective approaches in prostate cancer therapy. Herein, 
we provided evidence showing in human prostate cancer 
tissue endogenous CAMK2N1 expression was inversely 
correlated with AR. Recurrent patients with high AR levels 
had an improved recurrence-free survival if their tumor 
also expressed high CAMK2N1 protein levels. In prostate 
cancer cells, CAMK2N1 and AR signaling form an auto-
regulatory negative feedback loop, where CAMK2N1 
is down regulated by AR activation in response to 
androgen, while CAMK2N1 inhibits AR expression and 
activity through the CAMKII and AKT pathway. We 
speculate that activation of AR upon androgen binding 
inhibits CAMK2N1 gene expression in CSPC, and 
androgen ablation therapy promoted the expression of 
CAMK2N1, further causing inhibition of AR expression 
and activation. At the CRPC stage, abnormal activation 
of AR independent of androgen stimulus leads to the 
reduced CAMK2N1 expression, which further enhances 
AR expression and activation. 
Androgen ablation therapy is the frontline treatment 
for patients with advanced prostate cancers including 
metastatic and castration-resistant diseases. Since the 
majority of patients eventually develop castration-resistant 
cancer despite of initial favorable response, identification 
of molecules and mechanisms involved in castration 
resistance is critical for developing effective treatment 
of this deadly disease. We observed that knockdown of 
CAMK2N1 alleviated inhibition of growth to Casodex 
in castration-sensitive LNCaP cells and overexpression 
of CAMK2N1 induces inhibition of growth to Casodex 
in castration-resistant cells, indicating that re-expression 
of CAMK2N1 can restore Casodex sensitivity of prostate 
cancer cells. This study revealed a novel mechanism of 
CAM2KN1 underlying the development of castration and 
anti-androgen resistance.
In summary, we identify a biochemical and 
functional link between CAMK2N1 with reduced 
expression in advanced prostate cancer and androgen 
receptor signaling in prostate cancer. Furthermore, loss 
of CAMK2N1 expression contributes to prostate cancer 
growth and survival independent of androgen signaling 
and re-introduction of CAMK2N1 sensitizes castration-
resistant prostate cancer cells to anti-androgen therapy. 
Our results provide a compelling rationale for targeting 
the functional interaction between CAMK2N1 and AR 
signaling in clinical development to treat castration-
resistant prostate cancer.
MATERIALS AND METHODS
Cell culture, Plasmid construction, Reporter 
genes, Reagents, Expression vectors, and DNA 
transfection
Human prostate cancer LNCaP cells were obtained 
from ATCC and maintained in in RPMI 1640 medium 
(Invitrogen) supplemented with 10% FBS or 10% charcoal/
dextran stripped FBS (cFBS). C4-2 was maintained in 
RPMI 1640 medium (Invitrogen) supplemented with 10% 
FBS. The CAMK2N1 human cDNA clone was purchased 
from OriGene Technologies and subcloned into the EcoRI/
XhoI site of MSCV-IRES-GFP (Addgen) retroviral 
vector. pGIPZ lentiviral vector, pGIPZ-shCAMK2N1-1 
(shCA-1, 5’-TCAATAACAACCCGCTTGC-3’), 
pGIPZ-shCAMK2N1-3 (shCA-3, 
5’-TAGACACCAGGAGGTGCCT-3’) were purchased 
from Thermo Scientific. PSA-Luc MMTV-Luc, ARE4-
Luc reporter genes were described [30]. AKT inhibitor 
VIII was purchased from Perkin Elmer (Waltham, MA). 
LNCaP infected with GIPZ-Vector, shCA-1, shCA-3. C4-2 
infected with MSCV-IRES-GFP, MSCV-CAMK2N1-
IRES-GFP, pGIPZ-Vector, shCA-1, shCA-3. GFP positive 
cells were selected by FACS (Fluorescence Activated cell 
sorter). 
Cell Proliferation Assays
2×103 stable cells were seeded in 96-well plate in 
normal growth medium, and cell growth was measured 
daily by MTT assays using 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide. 
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Cell Cycle and Apoptosis Analysis 
Cell cycle parameters were determined by flow 
cytometry. Stable cells were processed by standard 
methods using propidium iodide staining of nuclear DNA. 
Each sample was analyzed by flow cytometry with a 
FACScan Flow Cytometer (Becton-Dickinson Biosciences, 
Mansfield, MA) using a 488 nm laser. Histograms were 
analyzed for cell cycle compartments using ModFit 
version 2.0 (Verity Software House, Topsham, ME). A 
minimum of 20,000 events were collected to maximize 
statistical validity of the compartmental analysis. The PE-
Annexin-V Apoptosis Detection Kit (BD Biosciences) was 
used to detect apoptosis by flow cytometry [31].
Western Blot 
Western blots were performed on DU145, PC3 and 
LNCaP cells as indicated. Cells were pelleted and lysed 
in buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1% Tween 20) 
supplemented with a protease inhibitor cocktail (Roche 
Diagnostics, Mannheim, Germany). Antibodies used for 
Western blots were: CAMK2N1 (SC-161427, Santa Cruz) 
and AR (SC-13062, Santa Cruz). 
Luciferase Assays 
Cells were seeded at a density of 1 x 105 cells in a 
24-well cell culture plate on the day prior to transfection 
with Superfect according to the manufacturer’s protocol 
(Qiagen, Valencia, CA). For reporter gene assays, a dose-
response was determined in each experiment with 50 
and 200 ng of expression vector and promoter reporter 
plasmids (0.5 μg). Luciferase activity was normalized for 
transfection efficiency using β-galactosidase reporter as 
an internal control. The fold effect of expression vector 
was determined with comparison to the value of the empty 
expression vector cassette and statistical analyses were 
performed using the t-test [32, 33].
Chromatin Immunoprecipitation (ChIP) Assays
ChIP assays were performed according to the 
protocol of the Upstate Biotechnology as described 
[34]. The primer sequence for PSA gene are PSA-
Enhancer: 5’-TGGGACAACTTGCAAACCTG-3’, 
5’-CCAGAGTAGGTCTGTTTTCAATCC-3’ [13]. 
Polyclonal antibody to AR (SC-13062, Santa Cruz) was 
used for IP and normal IgG was used as a negative control. 
One tenth of original DNA was used as an input control. 
RNA Isolation and Quantitative Real-time PCR 
(qRT-PCR) Assays 
Total RNA was isolated and reversely transcribed 
to cDNA using TRIzol reagent (Invitrogen) and iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, 
CA), respectively, according to the manufacturer’s 
instructions [35]. qRT-PCR was carried out in Bio-Rad 
CFX96 Real-Time PCR Detection System with iQ SYBR 
Green Supermix (Bio-Rad). Relative gene expression 
was normalized to 18s rRNA and calculated by using the 
2-∆∆Ct method. 
Immunohistochemistry (IHC) staining
Immunohistochemical analysis of human prostate 
cancer was conducted using a polyclonal CAMK2N1 
antibody 8. Human prostate cancer tissue arrays were 
purchased from Biomax. FOUR-micrometer sections 
were prepared from paraffin-embedded C4-2 Tumor 
tissues derived from nude mice, and tissues were extracted 
from paraffin. Tumor tissues were stained with primary 
antibody including Ki67 (RM-9106-S1, Thermo), Bcl-2 
(SC-7382, Santa cruz), Bax (SC-7480, Santa cruz), p21 
(SC-6246, Santa cruz).
Nude Mice Study
2 × 106 C4-2 cells knockdown CAMK2N1 were 
implanted subcutaneously into 4-6-week-old castrated mal 
nude mice purchased from Beijing HFK Bio-Technology.
co., LTD. Tumor growth was measured using a digital 
caliper every 5 days for 4-5 weeks. Tumor weight was 
measured when mice were sacrificed on day 32 after cell 
implantation.
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